Digital Health Intervention to Promote Quality of Life in Adults With Chronic Graft Versus Host Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06688942

Enrollment

Registered

2024-11-14

Start date

2024-12-04

Completion date

2026-09-25

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Graft-Versus-Host Disease, Quality of Life

Brief summary

The goal of this interventional study is to learn if the Horizons mobile application is feasible for survivors of allogeneic hematopoietic stem cell transplant who have chronic graft-versus-host disease. Participants will be asked to complete surveys and use the Horizons mobile application.

Interventions

BEHAVIORALHorizons App Intervention

Participants will receive access to the Horizons app intervention. The intervention pairs patient-centered information about chronic graft-versus-host disease with self-management strategies. Within each module, patients will engage in didactics and exercises that are relevant to the participant's chronic graft-versus-host disease concerns. The app contains 6 digital modules delivered via tablet over approximately 6 weeks. Each module should take up to approximately 20 minutes and are self-guided.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Underwent allogeneic hematopoietic stem cell transplant * Have moderate to severe chronic graft-versus-host disease * Currently receiving care at the Sylvester Comprehensive Cancer Center Bone Marrow Transplant Program * Able to use an Ipad to participate in the Horizons app intervention * Able to participate in study procedures in English

Exclusion criteria

* comorbid conditions or cognitive impairment that the treating clinician believes prohibits informed consent or participation in the intervention * Vulnerable patients, defined here as prisoners and pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Percentage of participant enrollment	Up to 8-week follow-up	Participant enrollment will be demonstrated if ≥60% eligible participants enroll.
Percentage of participant retention	Up to 8-week follow-up	Participant retention will be demonstrated if ≥80% participants are retained in the study.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLara Traeger, PhD

University of Miami

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026